Chemokine receptor patterns in lymphocytes mirror metastatic spreaDing in melanoma

Journal of Clinical Investigation

Volumn 126, Issue 3, 2016, Pages 921-937

  Jacquelot, Nicolas ^a,b   Enot, David P ^a   Flament, Caroline ^a   Vimond, Nadège ^a,c   Blattner, Carolin ^d,e   Pitt, Jonathan M ^a   Yamazaki, Takahiro ^a   Roberti, María Paula ^a   Daillère, Romain ^a,b   Vétizou, Marie ^a   Poirier Colame, Vichnou ^a   Semeraro, Michaëla ^a,f   Caignard, Anne ^g   Slingluff, Craig L ^h   Sallusto, Federica ⁱ   Rusakiewicz, Sylvie ^a   Weide, Benjamin ^j,k   Marabelle, Aurélien ^a   Kohrt, Holbrook ^l   Dalle, Stéphane ^m   Cavalcanti, Andréa ^a   Kroemer, Guido ^a,n,o,p,q,r   DI Giacomo, Anna Maria ^s   Maio, Michele ^s   Wong, Phillip ^t   Yuan, Jianda ^t   Wolchok, Jedd ^t   Umansky, Viktor ^d,e   Eggermont, Alexander ^a   Zitvogel, Laurence ^a,b   more..

^a INSTITUT GUSTAVE ROUSSY   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c CNRS UMS3655   (France)

^d GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^e UNIVERSITY OF HEIDELBERG   (Germany)

^f HÔPITAL NECKER ENFANTS MALADES   (France)

^g INSTITUT COCHIN   (France)

^h UNIVERSITY OF VIRGINIA   (United States)

ⁱ INSTITUTE FOR RESEARCH IN BIOMEDICINE   (Switzerland)

^j UNIVERSITY OF TÜBINGEN   (Germany)

^k UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^l STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^m CENTRE DE RECHERCHE EN CANCÉROLOGIE DE LYON   (France)

ⁿ CENTRE DE RECHERCHE DES CORDELIERS   (France)

^o INSERM   (France)

^p UNIVERSITÉ PARIS DESCARTES   (France)

^q SORBONNE UNIVERSITÉ   (France)

^r HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^s UNIVERSITY HOSPITAL OF SIENA   (Italy)

^t MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CD103 ANTIGEN; CD45RA ANTIGEN; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CCR10; CHEMOKINE RECEPTOR CCR6; CHEMOKINE RECEPTOR CCR7; CHEMOKINE RECEPTOR CCR9; CHEMOKINE RECEPTOR CXCR3; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR5; ANTINEOPLASTIC AGENT; IPILIMUMAB; MONOCLONAL ANTIBODY; TUMOR MARKER;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; HUMAN; HUMAN CELL; LYMPH NODE METASTASIS; LYMPHOCYTE FUNCTION; MAJOR CLINICAL STUDY; METASTASIS; METASTATIC MELANOMA; MOUSE; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; SKIN METASTASIS; TUMOR GROWTH; ANIMAL; C57BL MOUSE; CANCER TRANSPLANTATION; CASE CONTROL STUDY; FEMALE; IMMUNOLOGY; KAPLAN MEIER METHOD; LUNG TUMOR; MALE; MELANOMA; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RECEIVER OPERATING CHARACTERISTIC; SECONDARY; SKIN TUMOR; T LYMPHOCYTE; TUMOR CELL LINE;

ADULT; ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; CASE-CONTROL STUDIES; CELL LINE, TUMOR; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MELANOMA; MICE, INBRED C57BL; MIDDLE AGED; NEOPLASM TRANSPLANTATION; PROPORTIONAL HAZARDS MODELS; RECEPTORS, CHEMOKINE; ROC CURVE; SKIN NEOPLASMS; T-LYMPHOCYTES;

EID: 84959879714     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI80071     Document Type: Article

References (66)

1. Zlotnik A, Yoshie O. The chemokine superfamily revisited. Immunity. 2012;36(5):705-716.
2. Zweemer AJ, Toraskar J, Heitman LH, IJzerman AP. Bias in chemokine receptor signalling. Trends Immunol. 2014;35(6):243-252.
3. Reiter E, Lefkowitz RJ. GRKs and arrestins: roles in receptor silencing, trafficking and signaling. Trends Endocrinol Metab. 2006;17(4):159-165.
4. IUPHAR/BPS Guide to Pharmacology, http://www.guidetopharmacology.org. Accessed May 10, 2015.
5. Harlin H, et al. Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment. Cancer Res. 2009;69(7):3077-3085.
6. Mabuchi T, Chang TW, Quinter S, Hwang ST. Chemokine receptors in the pathogenesis and therapy of psoriasis. J Dermatol Sci. 2012;65(1):4-11.
7. Rivino L, Messi M, Jarrossay D, Lanzavecchia A, Sallusto F, Geginat J. Chemokine receptor expression identifies Pre-T helper (Th)1, Pre-Th2, and nonpolarized cells among human CD4+ central memory T cells. J Exp Med. 2004;200(6):725-735.
8. Duhen T, Geiger R, Jarrossay D, Lanzavecchia A, Sallusto F. Production of interleukin 22 but not interleukin 17 by a subset of human skin-homing memory T cells. Nat Immunol. 2009;10(8):857-863.
9. Chevalier N, et al. CXCR5 expressing human central memory CD4 T cells and their relevance for humoral immune responses. J Immunol. 2011;186(10):5556-5568.
10. Erdag G, et al. Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma. Cancer Res. 2012;72(5):1070-1080.
11. Galon J, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313(5795):1960-1964.
12. Zhang L, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 2003;348(3):203-213.
13. Fridman WH, Pagès F, Sautès-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer. 2012;12(4):298-306.
14. Messina JL, et al. 12-Chemokine gene signature identifies lymph node-like structures in melanoma: potential for patient selection for immunotherapy? Sci Rep. 2012;2:765.
15. Salerno EP, Olson WC, McSkimming C, Shea S, Slingluff CL Jr. T cells in the human metastatic melanoma microenvironment express site-specific homing receptors and retention integrins. Int J Cancer. 2014;134(3):563-574.
16. Clancy-Thompson E, King LK, Nunnley LD, Mullins IM, Slingluff CL Jr, Mullins DW. Peptide vaccination in Montanide adjuvant induces and GM-CSF increases CXCR3 and cutaneous lymphocyte antigen expression by tumor antigen-specific CD8 T cells. Cancer Immunol Res. 2013;1(5):332-339.
17. Salerno EP, et al. Activation, dysfunction and retention of T cells in vaccine sites after injection of incomplete Freund's adjuvant, with or without peptide. Cancer Immunol Immunother. 2013;62(7):1149-1159.
18. Mullins IM, et al. CXC chemokine receptor 3 expression by activated CD8+ T cells is associated with survival in melanoma patients with stage III disease. Cancer Res. 2004;64(21):7697-7701.
19. Hannani D, et al. Anticancer immunotherapy by CTLA4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25. Cell Res. 2015;25(2):208-224.
20. Robert C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364(26):2517-2526.
21. Hodi FS, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711-723.
22. Umansky V, et al. Melanoma-specific memory T cells are functionally active in Ret transgenic mice without macroscopic tumors. Cancer Res. 2008;68(22):9451-9458.
23. Sevko A, et al. Antitumor effect of paclitaxel is mediated by inhibition of myeloid-derived suppressor cells and chronic inflammation in the spontaneous melanoma model. J Immunol. 2013;190(5):2464-2471.
24. Umansky V, Sevko A. Ret transgenic mouse model of spontaneous skin melanoma: focus on regulatory T cells. Pigment Cell Melanoma Res. 2013;26(4):457-463.
25. Meyer C, et al. Chronic inflammation promotes myeloid-derived suppressor cell activation blocking antitumor immunity in transgenic mouse melanoma model. Proc Natl Acad Sci U S A. 2011;108(41):17111-17116.
26. Sevko A, et al. Cyclophosphamide promotes chronic inflammation-dependent immunosuppression and prevents antitumor response in melanoma. J Invest Dermatol. 2013;133(6):1610-1619.
27. Hong M, et al. Chemotherapy induces intratumoral expression of chemokines in cutaneous melanoma, favoring T-cell infiltration and tumor control. Cancer Res. 2011;71(22):6997-7009.
28. Amersi FF, et al. Activation of CCR9/CCL25 in cutaneous melanoma mediates preferential metastasis to the small intestine. Clin Cancer Res. 2008;14(3):638-645.
29. Ben-Baruch A. Organ selectivity in metastasis: regulation by chemokines and their receptors. Clin Exp Metastasis. 2008;25(4):345-356.
30. Yamamoto J, et al. Differential expression of the chemokine receptors by the Th1-and Th2-type effector populations within circulating CD4+ T cells. J Leukoc Biol. 2000;68(4):568-574.
31. Dengel LT, et al. Interferons induce CXCR3-cognate chemokine production by human metastatic melanoma. J Immunother. 2010;33(9):965-974.
32. Antonicelli F, et al. CXCL10 reduces melanoma proliferation and invasiveness in vitro and in vivo. Br J Dermatol. 2011;164(4):720-728.
33. Nardin A , et al. Dacarbazine promotes stromal remodeling and lymphocyte infiltration in cutaneous melanoma lesions. J Invest Dermatol. 2011;131(9):1896-1905.
34. Zou L, et al. Bone marrow is a reservoir for CD4+CD25+ regulatory T cells that traffic through CXCL12/CXCR4 signals. Cancer Res. 2004;64(22):8451-8455.
35. Roy LD, Sahraei M, Schettini JL, Gruber HE, Besmer DM, Mukherjee P. Systemic neutralization of IL-17A significantly reduces breast cancer associated metastasis in arthritic mice by reducing CXCL12/SDF-1 expression in the metastatic niches. BMC Cancer. 2014;14:225.
36. Bernhagen J, et al. MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment. Nat Med. 2007;13(5):587-596.
37. Schiraldi M, et al. HMGB1 promotes recruitment of inflammatory cells to damaged tissues by forming a complex with CXCL12 and signaling via CXCR4. J Exp Med. 2012;209(3):551-563.
38. Aguilar-Cazares D, et al. Relationship of dendritic cell density, HMGB1 expression, and tumor-infiltrating lymphocytes in non-small cell lung carcinomas. Appl Immunohistochem Mol Morphol. 2014;22(2):105-113.
39. Stenstad H, Svensson M, Cucak H, Kotarsky K, Agace WW. Differential homing mechanisms regulate regionalized effector CD8+ T cell accumulation within the small intestine. Proc Natl Acad Sci U S A. 2007;104(24):10122-10127.
40. Mowat AM, Agace WW. Regional specialization within the intestinal immune system. Nat Rev Immunol. 2014;14(10):667-685.
41. Wurbel M-A, Malissen M, Guy-Grand D, Malissen B, Campbell JJ. Impaired accumulation of antigen-specific CD8 lymphocytes in chemokine CCL25-deficient intestinal epithelium and lamina propria. J Immunol. 2007;178(12):7598-7606.
42. Evans-Marin HL, et al. Unexpected regulatory role of CCR9 in regulatory T cell development. PLoS One. 2015;10(7):e0134100.
43. Wang J, Li F, Wei H, Lian ZX, Sun R, Tian Z. Respiratory influenza virus infection induces intestinal immune injury via microbiota-mediated Th17 cell-dependent inflammation. J Exp Med. 2014;211(12):2397-2410.
44. Nakamoto N, et al. CCR9+ macrophages are required for acute liver inflammation in mouse models of hepatitis. Gastroenterology. 2012;142(2):366-376.
45. Mavigner M, et al. Altered CD4+ T cell homing to the gut impairs mucosal immune reconstitution in treated HIV-infected individuals. J Clin Invest. 2012;122(1):62-69.
46. Johnson-Holiday C, et al. CCL25 mediates migration, invasion and matrix metalloproteinase expression by breast cancer cells in a CCR9-dependent fashion. Int J Oncol. 2011;38(5):1279-1285.
47. Sharma PK et al. CCR9 mediates PI3K/AKT-dependent antiapoptotic signals in prostate cancer cells and inhibition of CCR9-CCL25 interaction enhances the cytotoxic effects of etoposide. Int J Cancer. 2010;127(9):2020-2030.
48. Johnson-Holiday C, Singh R, Johnson EL, Grizzle WE, Lillard JW Jr, Singh S. CCR9-CCL25 interactions promote cisplatin resistance in breast cancer cell through Akt activation in a PI3K-dependent and FAK-independent fashion. World J Surg Oncol. 2011;9:46.
49. Gupta P, et al. CCR9/CCL25 expression in non-small cell lung cancer correlates with aggressive disease and mediates key steps of metastasis. Oncotarget. 2014;5(20):10170-10179.
50. Ye LF, Huang J, Zhang LP, Chen Z. Intracellular expression profile and clinical significance of the CCR9-CCL25 chemokine receptor complex in nasopharyngeal carcinoma. J Laryngol Otol. 2015;129(10):1013-1019.
51. Zhong Y, et al. Expression of CC chemokine receptor 9 predicts poor prognosis in patients with lung adenocarcinoma. Diagn Pathol. 2015;10:101.
52. Chen HJ, et al. Comprehensive models of human primary and metastatic colorectal tumors in immunodeficient and immunocompetent mice by chemokine targeting. Nat Biotechnol. 2015;33(6):656-660.
53. Vela M, Aris M, Llorente M, Garcia-Sanz JA, Kremer L. Chemokine receptor-specific antibodies in cancer immunotherapy: achievements and challenges. Front Immunol. 2015;6:12.
54. Faaij CM, et al. A possible role for CCL27/ CTACK-CCR10 interaction in recruiting CD4 T cells to skin in human graft-versus-host disease. Br J Haematol. 2006;133(5):538-549.
55. Xia M, et al. CCR10 regulates balanced maintenance and function of resident regulatory and effector T cells to promote immune homeostasis in the skin. J Allergy Clin Immunol. 2014;134(3):634-644.
56. Monteagudo C, et al. CCL27-CCR10 and CXCL12-CXCR4 chemokine ligand-receptor mRNA expression ratio: new predictive factors of tumor progression in cutaneous malignant melanoma. Clin Exp Metastasis. 2012;29(6):625-637.
57. Fujita Y, et al. Presence of circulating CCR10+ T cells and elevated serum CTACK/CCL27 in the early stage of mycosis fungoides. Clin Cancer Res. 2006;12(9):2670-2675.
58. Zlotnik A, Burkhardt AM, Homey B. Homeostatic chemokine receptors and organ-specific metastasis. Nat Rev Immunol. 2011;11(9):597-606.
59. Torregrossa L, et al. CXCR4 expression correlates with the degree of tumor infiltration and BRAF status in papillary thyroid carcinomas. Mod Pathol. 2012;25(1):46-55.
60. Monteagudo C, Martin JM, Jorda E, Llombart-Bosch A. CXCR3 chemokine receptor immunoreactivity in primary cutaneous malignant melanoma: correlation with clinicopathological prognostic factors. J Clin Pathol. 2007;60(6):596-599.
61. O'Boyle G, et al. Inhibition of CXCR4-CXCL12 chemotaxis in melanoma by AMD11070. Br J Cancer. 2013;108(8):1634-1640.
62. Tubo NJ, Wurbel MA, Charvat TT, Schall TJ, Walters MJ, Campbell JJ. A systemically-administered small molecule antagonist of CCR9 acts as a tissue-selective inhibitor of lymphocyte trafficking. PLoS One. 2012;7(11):e50498.
63. Romero AI, et al. Regulation of CD4(+) NKG2D(+) Th1 cells in patients with metastatic melanoma treated with sorafenib: role of IL-15R and NKG2D triggering. Cancer Res. 2014;74(1):68-80.
64. Kruit WH, et al. Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE-3 protein in patients with detectable metastatic melanoma. Int J Cancer. 2005;117(4):596-604.
65. Pautier P, et al. Phase I clinical trial combining imatinib mesylate and IL-2 in refractory cancer patients: IL-2 interferes with the pharmacokinetics of imatinib mesylate. Oncoimmunology. 2013;2(2):e23079.
66. R Development Core Team. R: A Language And Environment For Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2011.